Tirzepatide Guide: Cost, Dosing, and Compounded Status in 2026

This is our editorial hub for tirzepatide. It covers what the drug is, what it costs in 2026, how the FDA-approved dose ladder works, and where the compounded tirzepatide market sits after the March 2025 regulatory shift. Each section below links to the full coverage on its topic. Our editorial voice is neutral. We do not sell tirzepatide, take affiliate payments on our pillar or explainer pages, or recommend specific telehealth providers.

What does tirzepatide do?

Tirzepatide is a once-weekly injectable peptide that acts on two gut hormone receptors at the same time: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both hormones regulate appetite, satiety, and the body's insulin response to food. Agonizing both receptors is what makes tirzepatide mechanistically different from semaglutide (Ozempic, Wegovy), which is a GLP-1-only agonist. For the full head-to-head efficacy data, see our semaglutide vs tirzepatide comparison.

The clinical effect shows up as reduced appetite, earlier fullness during meals, and slowed gastric emptying. In the phase 3 SURMOUNT-1 trial, 2,539 adults with obesity randomized to tirzepatide or placebo over 72 weeks, participants on the 15 mg maintenance dose lost an average of 20.9% of body weight, compared with 3.1% on placebo. For Type 2 diabetes (Mounjaro's FDA indication), the drug improves glycemic control and supports weight reduction as a secondary effect.

Tirzepatide is FDA-approved under two brand names: Zepbound for chronic weight management in adults with obesity (or overweight with at least one weight-related condition), for moderate-to-severe obstructive sleep apnea in adults with obesity, and Mounjaro for Type 2 diabetes mellitus. The drug molecule, the manufacturing site, and the dose ladder are identical between the two brands. The indications, patient populations, insurance coverage, and pricing differ.

Our Full Tirzepatide Coverage

Four deep-dive articles cover the main decisions patients and caregivers face in 2026: what tirzepatide costs, how it's dosed, what the side effects look like, and how the compounded market has changed. Each is linked below with a short summary of what you'll find.

How much does tirzepatide cost in 2026?

The monthly cost of tirzepatide in 2026 is not a single number. It branches on insurance status, which product you buy, and which pharmacy channel you use. Six main paths exist:

• Retail pharmacy without insurance: $1,080–$1,200+ per month at list price.
• LillyDirect single-dose vials (self-pay): $299 for the 2.5 mg starter dose, $399 for 5 mg, $449 for 7.5 mg and higher on the Self Pay Journey Program (consistent 45-day refill).
• Commercial insurance + manufacturer savings card: as low as $25 per fill for eligible patients.
• Compounded (personalized or combination formulations): varies by provider, typically $150–$600 per month in 2026.
• Medicare Part D: does not cover tirzepatide used primarily for weight loss; Mounjaro for Type 2 diabetes may be covered depending on plan formulary.
• Medicaid: coverage varies by state.

For the full breakdown, including how the LillyDirect Self Pay Journey Program works, the fine print on savings cards, public-program coverage, and hidden costs, see our complete tirzepatide cost guide.

What is the tirzepatide dose schedule?

The FDA-approved Zepbound label prescribes a structured six-step dose ladder for chronic weight management. Every patient starts at 2.5 mg once weekly for 4 weeks. After that, the dose steps up in 2.5 mg increments every 4 weeks, to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg, with at least 4 weeks on each dose before any increase. Reaching the 15 mg maximum takes at least 20 weeks, which is also the dose-escalation window SURMOUNT-1 used.

Only three doses are approved as long-term maintenance: 5 mg, 10 mg, and 15 mg. Patients who reach acceptable weight-loss response at a lower maintenance dose with tolerable side effects can stay there, the label explicitly permits stopping the ladder before 15 mg. For missed doses, the FDA instruction is: take the missed dose within 4 days (96 hours); beyond that, skip and resume on the next scheduled day.

For the full dosing detail, including SURMOUNT-1 efficacy at each dose, side-effect rates during titration, the 15 mg maximum, and when a lower maintenance dose is the better call, see our tirzepatide dosing guide.

Is compounded tirzepatide still legal in 2026?

From mid-2022 through late 2024, tirzepatide was on the FDA's drug shortage list. That status triggered an enforcement-discretion window under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which allowed state-licensed and FDA-registered pharmacies to compound copies of tirzepatide to meet patient demand. That window closed when the FDA declared the shortage resolved in December 2024.

A federal court denied a preliminary injunction on March 5, 2025, which meant state-licensed 503A pharmacies could no longer compound copies of tirzepatide. Outsourcing facilities (503B) lost their window on March 19, 2025. Licensed pharmacies still produce personalized or combination tirzepatide formulations, tirzepatide with vitamin B12, for example, under a narrower regulatory pathway for compounded medications that have a documented clinical difference from the commercial product.

For the full legal and clinical context, what 503A versus 503B means, how to evaluate a compounding pharmacy, and what patients currently on compounded tirzepatide should know, see our compounded tirzepatide explainer.

Frequently Asked Questions

What is tirzepatide?

Tirzepatide is a once-weekly injectable manufactured by Eli Lilly and Company that acts as a dual GLP-1 / GIP receptor agonist. The FDA has approved it under two brand names: Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity, and Mounjaro for Type 2 diabetes. The molecule is the same across both brands.

Is Zepbound the same as Mounjaro?

Yes, at the molecule and dose level. Zepbound and Mounjaro both contain tirzepatide at identical doses and follow the same FDA-approved 2.5 mg to 15 mg dose ladder. The difference is the FDA-approved indication, Zepbound for weight management and sleep apnea in obesity, Mounjaro for Type 2 diabetes, and the corresponding insurance coverage, pricing, and savings-card eligibility.

How much does tirzepatide cost per month in 2026?

Brand-name tirzepatide lists at roughly $1,080 to $1,086 per month before discounts. Zepbound single-dose vials through LillyDirect start at $299 per month for cash-pay patients. With commercial insurance and a manufacturer savings card, eligible patients can pay as little as $25 per fill. Compounded pricing varies widely and has shifted since the March 2025 FDA ruling.

What is the correct tirzepatide dose for weight loss?

The FDA-approved starting dose is 2.5 mg once weekly for 4 weeks. The dose then steps up in 2.5 mg increments every 4 weeks as tolerated to a maximum of 15 mg. Approved maintenance doses are 5 mg, 10 mg, and 15 mg weekly. Dose selection depends on weight-loss response and tolerability, in conversation with a prescriber.

Is compounded tirzepatide still available in 2026?

Direct copies of Zepbound and Mounjaro from compounding pharmacies are no longer broadly permitted after the March 2025 FDA ruling. Licensed 503A and 503B pharmacies still produce personalized or combination tirzepatide formulations under a narrower regulatory pathway, but the economics and availability changed significantly compared with the 2022 to 2024 shortage window.

Is there a generic version of tirzepatide?

No. Tirzepatide is under patent protection held by Eli Lilly and Company, with patent expiry not expected until the early 2030s. Compounded tirzepatide is not a generic, it is produced under a separate regulatory pathway for compounded preparations, not through an FDA-approved abbreviated new drug application.

How We Cover Tirzepatide

Every article in our tirzepatide coverage follows the standards described in our editorial policy. Every specific numerical or factual claim is verified live against a primary source in the drafting session: the FDA-approved label via DailyMed, peer-reviewed trial publications via PubMed, FDA guidance documents, or dated manufacturer pricing. Our coverage is reviewed by a credentialed expert before publication.

We do not take affiliate payments on our pillar or explainer pages, do not recommend specific telehealth providers, and do not accept directed coverage in exchange for editorial content. To report a factual error in any article, email editorial@healthymealsincentives.org, corrections are reviewed within five business days.